Travis LB, Curtis RE, Hankey BF, Fraumeni JF Jr. Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst. 1992;84:1422–7.

Article  CAS  PubMed  Google Scholar 

Brewer JD, Shanafelt TD, Otley CC, Roenigk RK, Cerhan JR, Kay NE, et al. Chronic lymphocytic leukemia is associated with decreased survival of patients with malignant melanoma and Merkel cell carcinoma in a SEER population-based study. J Clin Oncol. 2012;30:843–9.

Article  PubMed  Google Scholar 

Onajin O, Brewer JD. Skin cancer in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2012;10:571–6.

PubMed  Google Scholar 

Mansfield AS, Rabe KG, Slager SL, Schwager SM, Call TG, Brewer JD, et al. Skin cancer surveillance and malignancies of the skin in a community-dwelling cohort of patients with newly diagnosed chronic lymphocytic leukemia. J Oncol Pr. 2014;10:e1–4.

Article  Google Scholar 

Velez NF, Karia PS, Vartanov AR, Davids MS, Brown JR, Schmults CD. Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia. JAMA Dermatol. 2014;150:280–7.

Article  PubMed  Google Scholar 

Axelrod H, Pienta KJ. AXL as a mediator of cellular growth and survival. Oncotarget. 2014;5:8818–52.

Article  PubMed  PubMed Central  Google Scholar 

Auyez A, Sayan AE, Kriajevska M, Tulchinsky E. AXL receptor in cancer metastasis and drug resistance: when normal functions go askew. Cancers. 2021;13:20210928.

Article  Google Scholar 

Ghosh AK, Secreto C, Boysen J, Sassoon T, Shanafelt TD, Mukhopadhyay D, et al. The novel receptor tyrosine kinase AXL is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood. 2011;117:1928–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger JS, et al. AXL, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood. 2013;122:2443–52.

Article  CAS  PubMed  Google Scholar 

Green J, Ikram M, Vyas J, Patel N, Proby CM, Ghali L, et al. Overexpression of the AXL tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours. Br J Cancer. 2006;94:1446–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Polo A, Luo Z, Gerarduzzi C, Chen X, Little JB, Yuan ZM. AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex. J Mol Cell Biol. 2017;9:154–65.

Article  PubMed  Google Scholar 

Boshuizen J, Koopman LA, Krijgsman O, Shahrabi A, van den Heuvel EG, Ligtenberg MA, et al. Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. Nat Med. 2018;24:203–12.

Article  CAS  PubMed  Google Scholar 

Ghosh AK, Secreto CR, Knox TR, Ding W, Mukhopadhyay D, Kay NE. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood. 2010;115:1755–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sinha S, Boysen J, Nelson M, Secreto C, Warner SL, Bearss DJ, et al. Targeted AXL inhibition primes chronic lymphocytic leukemia B cells to apoptosis and shows synergistic/additive effects in combination with BTK inhibitors. Clin Cancer Res. 2015;21:2115–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Diest PJ, van Dam P, Henzen-Logmans SC, Berns E, van der Burg ME, Green J, et al. A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group. J Clin Pathol. 1997;50:801–4.

Article  PubMed  PubMed Central  Google Scholar 

Mollard A, Warner SL, Call LT, Wade ML, Bearss JJ, Verma A, et al. Design, synthesis and biological evaluation of a series of novel AXL kinase inhibitors. ACS Med Chem Lett. 2011;2:907–12. https://doi.org/10.1021/ml200198x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA. 2008;105:12885–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jayachandran M, Lugo G, Heiling H, Miller VM, Rule AD, Lieske JC. Extracellular vesicles in urine of women with but not without kidney stones manifest patterns similar to men: a case control study. Biol Sex Differ. 2015;6:2.

Article  PubMed  PubMed Central  Google Scholar 

Jayachandran M, Litwiller RD, Owen WG, Heit JA, Behrenbeck T, Mulvagh SL, et al. Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. Am J Physiol Heart Circ Physiol. 2008;295:H931.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gajiwala KS, Grodsky N, Bolanos B, Feng J, Ferre R, Timofeevski S, et al. The AXL kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase. J Biol Chem. 2017;292:15705–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li YY, Tao YW, Gao S, Li P, Zheng JM, Zhang SE, et al. Cancer-associated fibroblasts contribute to oral cancer cells proliferation and metastasis via exosome-mediated paracrine miR-34a-5p. EBioMedicine. 2018;36:209–20.

Article  PubMed  PubMed Central  Google Scholar 

Sinha S, Boysen JC, Chaffee KG, Kabat BF, Slager SL, Parikh SA, et al. Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy. Oncotarget. 2018;9:37173–84.

Article  PubMed  PubMed Central  Google Scholar 

Kim H, Lee S, Shin E, Seong KM, Jin YW, Youn H, et al. The emerging roles of exosomes as EMT regulators in cancer. Cells. 2020;9:20200402.

Google Scholar 

Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson KL. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene. 2014;33:1316–24.

Article  CAS  PubMed  Google Scholar 

Zhang G, Kong X, Wang M, Zhao H, Han S, Hu R. et al. AXL is a marker for epithelial-mesenchymal transition in esophageal squamous cell carcinoma. Oncol Lett. 2018;15:1900–6.

PubMed  Google Scholar 

Gjerdrum C, Tiron C, Hoiby T, Stefansson I, Haugen H, Sandal T, et al. AXL is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci USA. 2010;107:1124–9.

Article  CAS  PubMed  Google Scholar 

Ribatti D, Tamma R, Annese T. Epithelial-mesenchymal transition in cancer: a historical overview. Transl Oncol. 2020;13:100773.

Article  PubMed  PubMed Central  Google Scholar 

Campbell K, Casanova J. A common framework for EMT and collective cell migration. Development. 2016;143:4291–4300.

Article  CAS  PubMed  Google Scholar 

Levi F, Randimbison L, Te VC, La Vecchia C. Non-Hodgkin’s lymphomas, chronic lymphocytic leukaemias and skin cancers. Br J Cancer. 1996;74:1847–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Greene MH, Hoover RN, Fraumeni JF Jr. Subsequent cancer in patients with chronic lymphocytic leukemia-a possible immunologic mechanism. J Natl Cancer Inst. 1978;61:337–40.

CAS  PubMed  Google Scholar 

Ishdorj G, Beiggi S, Nugent Z, Streu E, Banerji V, Dhaliwal D, et al. Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival. Leuk Lymphoma 2019;60:3204–13.

Kleinstern G, Rishi A, Achenbach SJ, Chaffee KR, Kay NE, Shanafelt TD, et al. Skin cancers among chronic lymphocytic leukemia (CLL) patients - the effect of uv radiation and cll clinical characteristics. Blood-ASH Abstr. 2016;128:4772.